

AMENDMENTS TO THE CLAIMS

1. (Original) An isolated regulatory CD4⁺CD25⁺ T cell which comprises at least one galectin-10 as target or marker.
2. (Original) An isolated T-regulatory cell as claimed in claim 1 which consists of the CD4⁺CD25⁺β7⁺ subpopulation.
3. (Currently amended) An isolated T-regulatory cell as claimed in claim 1 ~~or 2~~ which contains at least one human galectin-10 or a homologous protein.
4. (Currently amended) An isolated T-regulatory cell as claimed in ~~one of claims 1 to 3~~ claim 1 which contains at least one galectin selected from the group consisting of SEQ ID No. 1 ~~or and~~ SEQ ID No. 2.
5. (Currently amended) An isolated T-regulatory cell as claimed in ~~one of claims 1 to 4~~ claim 1 which contains at least one galectin selected from the group consisting of SEQ ID No. 1 ~~or and~~ SEQ ID No. 2 having the isoforms: a.) apparent molecular weight of 14 kDa and a pI of 6.7, b.) apparent molecular weight of 13.5 kDa and a pI of 5.9, c.) apparent molecular weight of 13 kDa and a pI of 5.9.
6. (Original) An isolated T-regulatory cell as claimed in claim 5, wherein the isoforms are selected from the group SEQ ID No. 8 to SEQ ID No. 64.
7. (Currently amended) An isolated regulatory T cell as claimed in ~~one of claims 1 to 6~~ claim 1, characterized in that ~~at least one galectin as claimed in one of claims 1-6 said at least one galactin -10~~ is secreted, is located in the membrane or is presented on the surface of the T-regulatory cell or in the cytosol.
8. (Currently amended) An isolated regulatory T cell as claimed in ~~one of claims 1 to 7~~ claim 1, characterized in that ~~said at least one galectin-10 as claimed in one of claims 1 to 6~~ is concentrated in the regulatory T cell or on the surface of the regulatory T cell.

9. (Currently amended) An isolated regulatory T cell as claimed in ~~one of claims 1 to 8~~ claim 1, characterized in that at least one nucleic acid encoding at least one galectin is present and, ~~where appropriate~~ optionally, comprises one or more noncoding sequences, ~~and/or~~ a poly(A) sequence, ~~and/or~~ recognition sequences ~~and/or~~ or regulatory sequences such as promoter or enhancer sequences.

10. (Currently amended) An isolated T-regulatory cell as claimed in ~~one of claims 1 to 9~~ claim 1, characterized in that the nucleic acid sequence is selected from SEQ ID No. 6.

11. (Currently amended) A marker or a target consisting of an isolated regulatory T cell which contains galectin as claimed in ~~one of claims 1 to 10~~ claim 1.

12. (Currently amended) A binding agent which binds at least one isolated regulatory T cell as claimed in ~~one of claims 1-10~~ claim 1 ~~or native regulatory T cell as claimed in claim 11,~~ wherein said binding agent is selected from the group consisting of inhibitor, agonist, antagonist, probe, antibody ~~or~~ and immunomodulator.

13. (Currently amended) A binding agent which binds at least one isolated regulatory T cell as claimed in ~~one of claims 1-10~~ claim 1 ~~or native regulatory T cell as claimed in claim 11,~~ wherein the binding agent exhibits one or more epitopes directed against ~~galectin as claimed in one of claims 1-6~~ galactin-10 and additionally exhibits one or more epitopes directed against a surface protein.

14. (Original) A binding agent as claimed in claim 13, wherein the surface protein is selected from the group CD25, CD44, CD45, GITR, CTLA-4 and Fox P3.

15. (Currently amended) A binding agent as claimed in ~~one of claims 13 to 14~~ claim 13, selected from the group consisting of antibody, inhibitor, agonist, antagonist, probe ~~or~~ and immunomodulator.

16. (Currently amended) A binding agent as claimed in ~~one of claims 12 to 15~~ claim 12, wherein the isolated regulatory T cell ~~or native regulatory T cell containing at least one galectin as claimed in one of claims 1-6~~ is activated or inactivated.

17. (Currently amended) A pharmaceutical which comprises at least one binding agent as claimed in ~~one of claims 12 to 16~~ claim 12 or isolated T regulatory cells as claimed in ~~one of claims 1 to 10~~.

18. (Original) A pharmaceutical as claimed in claim 17 for the treatment and therapy of diseases, specifically allergies, autoimmune diseases, in particular rheumatoid arthritis, multiple sclerosis or Crohn's disease, chronic inflammation, asthma, immunodeficiency diseases, AIDS, transplant rejection and cancer diseases as well as diabetes.

19. (Original) A pharmaceutical as claimed in claim 18, wherein the autoimmune diseases are selected from the group: alopecia areata, Bechterew's disease, antiphospholipid syndrome, Addison's disease, Behcet's disease, sprue celiac disease, chronic fatigue immune dysfunction syndrome (CFIDS), polyneuropathy, Churg-Strauss syndrome (granulomatosis), CREST syndrome (Raynaud's syndrome), cold agglutinin disease, cryoglobulinemia, fibromyalgia, fibromyositis, Basedow's disease, Guillain-Barré syndrome, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia, IgA nephropathy, lichen planus, Ménière's disease, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, primary agammaglobulinemia, biliary cirrhosis, psoriasis, Reiter's disease, sarcoidosis, Sjögren's disease, Takayasu arteritis, vasculitis, vitiligo and Wegener's granulomatosis.

20. (Currently amended) A test system which comprises at least one binding agent and at least one regulatory T cell containing galectins as claimed in ~~one of claims 1-6~~ claim 1 for identifying suitable binding agents or regulatory T cells, ~~preferably those possessing elevated suppressive properties~~.

21. (Currently amended) A test system which comprises at least one regulatory T cell containing galectins as claimed in ~~one of claims 1-6~~ claim 1 and at least one target cell, ~~in particular selected from the group consisting of~~ T cell, B cell, macrophage, predendritic cell, dendritic cell, embryonic cell ~~and/or and~~ fibroblast which ~~is/are is~~ incubated with at least one regulatory T cell for the in-vitro detection of ~~suppressive properties, in particular suppression of the cellular immune response of effector cells of the immune system, in particular selected from the group consisting of~~ B cells, NK cells, ~~preferably~~ T cells and T helper cells.

22. (Original) The test system as claimed in claim 21, wherein the effector cells are mammalian cells, in particular human or murine cells or an immune cell line and/or a cultured primary immune cell.

23. (Currently amended) The test system as claimed in claim 21 or 22, wherein comprising at least one further substance which can elicit an immune response, such as, which substance is selected from the group consisting of proteins, epitopes, protein fragments, antigens or and binding agents, is/are incubated.

24. (Currently amended) A diagnostic agent which comprises a test system as claimed in ~~one of claims 20 to 23~~ claim 20 and, where appropriate optionally, a pharmaceutically acceptable support.

25. (Original) A diagnostic agent as claimed in claim 24 for diagnosing diseases, specifically allergies, autoimmune diseases, in particular rheumatoid arthritis, multiple sclerosis or Crohn's disease, chronic inflammation, asthma, immunodeficiency diseases, AIDS, transplant rejection and cancer diseases as well as diabetes.

26. (Original) A diagnostic agent as claimed in claim 25 for diagnosing diseases, specifically autoimmune diseases selected from the group: alopecia areata, Bechterew's disease, antiphospholipid syndrome, Addison's disease, Behcet's disease, sprue celiac disease, chronic fatigue immune dysfunction syndrome (CFIDS), polyneuropathy, Churg-Strauss syndrome (granulomatosis), CREST syndrome (Raynaud's syndrome), cold agglutinin disease, cryoglobulinemia, fibromyalgia, fibromyositis, Basedow's disease, Guillain-Barré syndrome, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia, IgA nephropathy, lichen planus, Ménière's disease, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, primary agammaglobulinemia, biliary cirrhosis, psoriasis, Reiter's disease, sarcoidosis, Sjögren's disease, Takayasu arteritis, vasculitis, vitiligo and Wegener's granulomatosis.